<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01362959</url>
  </required_header>
  <id_info>
    <org_study_id>NicGoWell1.0</org_study_id>
    <secondary_id>2011-002458-29</secondary_id>
    <nct_id>NCT01362959</nct_id>
  </id_info>
  <brief_title>Nicotine Replacement Therapy in the Intensive Care Unit</brief_title>
  <acronym>NicGoWell</acronym>
  <official_title>Nicotine Replacement Therapy in the Intensive Care Unit: a Randomized, Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gelderse Vallei Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deventer Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wageningen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gelderse Vallei Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether transdermal nicotine replacement therapy is
      safe and effective for treating nicotine withdrawal symptoms in the critically ill smoking
      patient.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cigarette smoking remains the leading cause of preventable disease and premature death
      worldwide. There are about 1.2 billion smokers in the world, half of whom will die from
      diseases caused by smoking. Smoking causes 5 million deaths per year, and if present trends
      continue, 10 million smokers per year are projected to die by 2025.

      Furthermore, abstinence from the highly addictive tobacco products can lead to withdrawal
      symptoms. Although these symptoms are non-life threatening in healthy and hospitalized adults
      they are not well described in the mechanically ventilated active smoking patient.

      Retrospective studies found a higher, lower or equal mortality in critically ill patients
      receiving nicotine replacement therapy compared to patients receiving no nicotine
      replacement.

      Because of these conflicting results and the absence of a randomized controlled trial
      studying the efficacy and safety of transdermal nicotine replacement therapy in the
      critically ill smoking patient a clinical study will be conducted.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>On day 30</time_frame>
    <description>Last day study period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>90-day mortality</measure>
    <time_frame>Day 90 followup</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient location</measure>
    <time_frame>On day 30, day 90 followup</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total maximum SOFA score</measure>
    <time_frame>30 days</time_frame>
    <description>summing worst scores for each organ system</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Delta SOFA score</measure>
    <time_frame>30 days</time_frame>
    <description>total maximum SOFA score minus admission total SOFA score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean RASS-score</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Highest RASS-score</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lowest RASS-score</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hours RASS-score outside optimal range (&lt;-3 and/or &gt;+1)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hours RASS-score outside optimal range (&lt;-3 and/or &gt;+1) indexed by the overall duration of sedation</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hours with delirium</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of self-extubations</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of self-removed catheters</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of new nosocomial infections (CDC criteria)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total dose of sedatives, analgesics and antipsychotics in mg or Î¼g/kg</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hours of physical restraint</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sedation-free hours</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of stay, ICU (hours)</measure>
    <time_frame>30 days, day 90 followup</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of stay, hospital (hours)</measure>
    <time_frame>30 days, day 90 followup</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intensive Care Unit mortality</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Delirium</condition>
  <condition>Psychomotor Agitation</condition>
  <condition>Substance Withdrawal Syndrome</condition>
  <condition>Nicotine Replacement Therapy</condition>
  <arm_group>
    <arm_group_label>Nicotine patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control patch</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control product is a look-alike patch compared to the test product, containing no nicotine or other active substances.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal nicotine patch</intervention_name>
    <description>The test product is a transdermal nicotine patch. The dosage of the test product depends on the amount of cigarettes used by a specific patient (21 or more or less than 21) delivering 21 or 14 mg nicotine/24 hrs. During the study period of thirty (30) days a patch will be applicated daily.</description>
    <arm_group_label>Nicotine patch</arm_group_label>
    <other_name>Nicotinell patch, regulated delivery 35 mg. RVG 14830</other_name>
    <other_name>Nicotinell patch, regulated delivery 52.5 mg. RVG 14831</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cutaneous patch, containing no active substances</intervention_name>
    <description>During the study period of thirty (30) days, the control product will be applicated daily.</description>
    <arm_group_label>Control patch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Any patient admitted to the intensive care unit must meet all of the
        following criteria to be eligible for the study:

          -  Critically ill active smoking patient

          -  Being mechanically ventilated

          -  Start of study product application within 48 hours after ICU admission

          -  Expected to be mechanically ventilated for more than 48 hours after start of
             application of the study product

        Exclusion Criteria: Any patient admitted to the intensive care unit meeting one or more of
        the following criteria is not eligible for the study:

          -  Patient younger than 18 years

          -  Patient or next of kin denying research authorization

          -  Pregnancy

          -  Breastfeeding women

          -  History of chronic dementia or psychosis

          -  (Acute) neurologic disease on admission, possibly confounding study objectives (TBI,
             stroke, ICH/SAH, seizures, meningitis, encephalitis, intracranial tumor)

          -  Patient receiving any form of NRT within two weeks before admission

          -  Patient not understanding Dutch

          -  Patient with acute myocardial infarction

          -  Patient with severe cardiac arrhythmia

          -  Patient with unstable or deteriorating angina pectoris

          -  Patient with generalized acute or chronic skin diseases interfering with NRT
             absorption

          -  Patient with severe hearing deficiency

          -  Moribund patient

          -  Patient with known hypersensibility to nicotine or components of the transdermal
             therapeutic system

          -  Patient with known hypersensibility to patches

          -  Patient participating in an other study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ben Jong,de, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gelderse Vallei Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gelderse Vallei Hospital</name>
      <address>
        <city>Ede</city>
        <state>Gelderland</state>
        <zip>6716 RP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deventer Hospital</name>
      <address>
        <city>Deventer</city>
        <state>Overijssel</state>
        <zip>7416 SE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.geldersevallei.nl</url>
    <description>Website Gelderse Vallei Hospital</description>
  </link>
  <reference>
    <citation>Hays JT, Ebbert JO. Adverse effects and tolerability of medications for the treatment of tobacco use and dependence. Drugs. 2010 Dec 24;70(18):2357-72. doi: 10.2165/11538190-000000000-00000. Review.</citation>
    <PMID>21142259</PMID>
  </reference>
  <reference>
    <citation>Moss M, Burnham EL. Alcohol abuse in the critically ill patient. Lancet. 2006 Dec 23;368(9554):2231-42. Review.</citation>
    <PMID>17189035</PMID>
  </reference>
  <reference>
    <citation>Benowitz NL. Nicotine addiction. N Engl J Med. 2010 Jun 17;362(24):2295-303. doi: 10.1056/NEJMra0809890. Review.</citation>
    <PMID>20554984</PMID>
  </reference>
  <reference>
    <citation>Hatsukami DK, Stead LF, Gupta PC. Tobacco addiction. Lancet. 2008 Jun 14;371(9629):2027-38. doi: 10.1016/S0140-6736(08)60871-5. Review.</citation>
    <PMID>18555914</PMID>
  </reference>
  <reference>
    <citation>Mills EJ, Wu P, Lockhart I, Wilson K, Ebbert JO. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. Tob Induc Dis. 2010 Jul 13;8:8. doi: 10.1186/1617-9625-8-8.</citation>
    <PMID>20626883</PMID>
  </reference>
  <reference>
    <citation>Lucidarme O, Seguin A, Daubin C, Ramakers M, Terzi N, Beck P, Charbonneau P, du Cheyron D. Nicotine withdrawal and agitation in ventilated critically ill patients. Crit Care. 2010;14(2):R58. doi: 10.1186/cc8954. Epub 2010 Apr 9.</citation>
    <PMID>20380688</PMID>
  </reference>
  <reference>
    <citation>Mayer SA, Chong JY, Ridgway E, Min KC, Commichau C, Bernardini GL. Delirium from nicotine withdrawal in neuro-ICU patients. Neurology. 2001 Aug 14;57(3):551-3.</citation>
    <PMID>11502936</PMID>
  </reference>
  <reference>
    <citation>Moreno R, Vincent JL, Matos R, MendonÃ§a A, Cantraine F, Thijs L, Takala J, Sprung C, Antonelli M, Bruining H, Willatts S. The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM. Intensive Care Med. 1999 Jul;25(7):686-96.</citation>
    <PMID>10470572</PMID>
  </reference>
  <reference>
    <citation>Lee AH, Afessa B. The association of nicotine replacement therapy with mortality in a medical intensive care unit. Crit Care Med. 2007 Jun;35(6):1517-21.</citation>
    <PMID>17452926</PMID>
  </reference>
  <reference>
    <citation>Paciullo CA, Short MR, Steinke DT, Jennings HR. Impact of nicotine replacement therapy on postoperative mortality following coronary artery bypass graft surgery. Ann Pharmacother. 2009 Jul;43(7):1197-202. doi: 10.1345/aph.1L423. Epub 2009 Jun 30.</citation>
    <PMID>19567657</PMID>
  </reference>
  <reference>
    <citation>Seder DB, Schmidt JM, Badjatia N, Fernandez L, Rincon F, Claassen J, Gordon E, Carrera E, Kurtz P, Lee K, Connolly ES, Mayer SA. Transdermal nicotine replacement therapy in cigarette smokers with acute subarachnoid hemorrhage. Neurocrit Care. 2011 Feb;14(1):77-83. doi: 10.1007/s12028-010-9456-9.</citation>
    <PMID>20949331</PMID>
  </reference>
  <reference>
    <citation>Cartin-Ceba R, Warner DO, Hays JT, Afessa B. Nicotine replacement therapy in critically ill patients: a prospective observational cohort study. Crit Care Med. 2011 Jul;39(7):1635-40. doi: 10.1097/CCM.0b013e31821867b8.</citation>
    <PMID>21494111</PMID>
  </reference>
  <reference>
    <citation>Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008 Jun;36(5):309-32. doi: 10.1016/j.ajic.2008.03.002. Erratum in: Am J Infect Control. 2008 Nov;36(9):655.</citation>
    <PMID>18538699</PMID>
  </reference>
  <reference>
    <citation>Centers for Disease Control and Prevention (CDC). Vital signs: central line-associated blood stream infections--United States, 2001, 2008, and 2009. MMWR Morb Mortal Wkly Rep. 2011 Mar 4;60(8):243-8.</citation>
    <PMID>21368740</PMID>
  </reference>
  <reference>
    <citation>Hsieh SJ, Ware LB, Eisner MD, Yu L, Jacob P 3rd, Havel C, Goniewicz ML, Matthay MA, Benowitz NL, Calfee CS. Biomarkers increase detection of active smoking and secondhand smoke exposure in critically ill patients. Crit Care Med. 2011 Jan;39(1):40-5. doi: 10.1097/CCM.0b013e3181fa4196.</citation>
    <PMID>20935560</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2011</study_first_submitted>
  <study_first_submitted_qc>May 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2011</study_first_posted>
  <last_update_submitted>August 26, 2016</last_update_submitted>
  <last_update_submitted_qc>August 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gelderse Vallei Hospital</investigator_affiliation>
    <investigator_full_name>drs. B. de Jong</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Delirium</keyword>
  <keyword>Psychomotor Agitation</keyword>
  <keyword>Substance Withdrawal Syndrome</keyword>
  <keyword>Nicotine replacement therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Substance Withdrawal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 3, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

